Circulating tumor DNA in cancer diagnosis, monitoring, and prognosis

Circulating tumor DNA in cancer diagnosis, monitoring, and prognosis

Abstract Background Circulating tumor DNA (ctDNA) has become one of the crucial components for cancer detection with the increase of precision medicine practice. ctDNA has great potential as a blood-based biomarker for the detection and treatment of cancer in its early stages. The purpose of this ar...

Full description

Bibliographic Details
Main Authors:	Sudeepto Saha, Yusha Araf, Salman Khan Promon
Format:	Article
Language:	English
Published:	SpringerOpen 2022-02-01
Series:	Journal of the Egyptian National Cancer Institute
Subjects:	Circulating tumor DNA (ctDNA) Cancer biomarkers Cancer diagnosis
Online Access:	https://doi.org/10.1186/s43046-022-00109-4

Similar Items

Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis
by: Estela Sánchez-Herrero, et al.
Published: (2022-07-01)

Circulating Tumor DNA (ctDNA) Clearance May Predict Treatment Response in Neoadjuvant Colorectal Cancer Management
by: Britney Niemann, et al.
Published: (2024-03-01)

Circulating Tumor Cells: From the Laboratory to the Cancer Clinic
by: Ruchi Agashe, et al.
Published: (2020-08-01)

From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real‐world setting
by: Steven P. Rowe, et al.
Published: (2018-10-01)

Editorial: Circulating tumor DNA in cancer: a role as a response and monitoring “next-generation” biomarker in cancer therapy
by: Saeid Latifi-Navid, et al.
Published: (2023-06-01)

Review of the clinical applications and technological advances of circulating tumor DNA in cancer monitoring
by: Chang Y, et al.
Published: (2017-10-01)

Circulating Cell-Free DNA-Based Methylation Pattern in Saliva for Early Diagnosis of Head and Neck Cancer
by: Natalia Birknerova, et al.
Published: (2022-10-01)

The Use of Circulating Tumor DNA to Monitor and Predict Response to Treatment in Colorectal Cancer
by: Mifanwy Reece, et al.
Published: (2019-11-01)

Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening
by: Jacob J. Adashek, et al.
Published: (2021-07-01)

Circulating Tumor DNA and Management of Colorectal Cancer
by: Matthew Krell, et al.
Published: (2023-12-01)

Clinical Evidence of Circulating Tumor DNA Application in Aggressive Breast Cancer
by: Brahim El Hejjioui, et al.
Published: (2023-01-01)

Role of Circulating Tumor DNA in Gastrointestinal Cancers: Update From Abstracts and Sessions at ASCO 2018
by: Faisal Shahjehan, et al.
Published: (2019-05-01)

The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review
by: Ian A. Cree, et al.
Published: (2017-10-01)

Monitoring of Early Changes of Circulating Tumor DNA in the Plasma of Rectal Cancer Patients Receiving Neoadjuvant Concomitant Chemoradiotherapy: Evaluation for Prognosis and Prediction of Therapeutic Response
by: Filip Pazdirek, et al.
Published: (2020-07-01)

Clinical applications and utility of ctDNA in cervical cancer and its precursor lesions: from screening to predictive biomarker
by: Li Li, et al.
Published: (2023-12-01)

Methylated Circulating Tumor DNA in Blood as a Tool for Diagnosing Lung Cancer: A Systematic Review and Meta-Analysis
by: Morten Borg, et al.
Published: (2023-08-01)

Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update
by: Joanna Kapeleris, et al.
Published: (2022-03-01)

Liquid Biopsy in Diagnosis and Prognosis of Non-Metastatic Prostate Cancer
by: Alexey S. Rzhevskiy, et al.
Published: (2022-12-01)

Circulating Tumour Cells (CTC), Head and Neck Cancer and Radiotherapy; Future Perspectives
by: Vanathi Perumal, et al.
Published: (2019-03-01)

Use of Circulating Tumour DNA (ctDNA) for Measurement of Therapy Predictive Biomarkers in Patients with Cancer
by: Michael J. Duffy, et al.
Published: (2022-01-01)

Role of Circulating Tumor DNA in Hematological Malignancy
by: Miho Ogawa, et al.
Published: (2021-04-01)

The Specific Gravity-Free Method for the Isolation of Circulating Tumor KRAS Mutant DNA and Exosome in Colorectal Cancer
by: Tae Hee Lee, et al.
Published: (2021-08-01)

Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumors
by: Jiaping Li, et al.
Published: (2020-08-01)

Predictive impact of human papillomavirus circulating tumor DNA in treatment response monitoring of HPV‐associated cancers; a meta‐analysis on recurrent event endpoints
by: Abbas Karimi, et al.
Published: (2023-09-01)

Circulating Tumor DNA in Gastric Adenocarcinoma: Future Clinical Applications and Perspectives
by: Giulia Grizzi, et al.
Published: (2023-05-01)

Basic Science with Preclinical Models to Investigate and Develop Liquid Biopsy: What Are the Available Data and Is It a Fruitful Approach?
by: Benedetta Cena, et al.
Published: (2022-05-01)

Basic ctDNA Panel Promises Affordable Clinical Validity in Colon Cancer Patients but Not in Pancreas Cancer Patients
by: Mandy Radefeldt, et al.
Published: (2023-11-01)

Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review
by: Lemei Zhu, et al.
Published: (2023-08-01)

Erratum: Is liquid biopsy the future commutator of decision-making in liver transplantation for hepatocellular carcinoma?
by: Frontiers Production Office
Published: (2023-03-01)

Is liquid biopsy the future commutator of decision-making in liver transplantation for hepatocellular carcinoma?
by: Stéphanie Gonvers, et al.
Published: (2022-08-01)

High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2− postmenopausal breast cancer patients treated with everolimus and exemestane
by: Dinja T. Kruger, et al.
Published: (2020-03-01)

Circulating tumor DNA: Opportunities and challenges for pharmacometric approaches
by: Benjamin Ribba, et al.
Published: (2023-03-01)

Integrating Cycled Enzymatic DNA Amplification and Surface-Enhanced Raman Scattering for Sensitive Detection of Circulating Tumor DNA
by: Xinxing Miao, et al.
Published: (2021-05-01)

Emerging Lab-on-a-Chip Approaches for Liquid Biopsy in Lung Cancer: Status in CTCs and ctDNA Research and Clinical Validation
by: Ângela Carvalho, et al.
Published: (2021-04-01)

Comprehensive Gene Mutation Profiling of Circulating Tumor DNA in Ovarian Cancer: Its Pathological and Prognostic Impact
by: Tomoko Noguchi, et al.
Published: (2020-11-01)

Clinical Utility of Circulating Tumor DNA in Advanced Rare Cancers
by: Hitomi Sumiyoshi Okuma, et al.
Published: (2021-11-01)

Monitoring of circulating tumour DNA in advanced pancreatic ductal adenocarcinoma predicts clinical outcome and reveals disease progression earlier than radiological imaging
by: Karin Hestnes Edland, et al.
Published: (2023-09-01)

Harnessing ctDNA in Advanced Melanoma: A Promising Tool for Informed Clinical Decisions
by: Rugile Pikturniene, et al.
Published: (2024-03-01)

The potential for liquid biopsies in the precision medical treatment of breast cancer
by: Victoria A. Forte, et al.
Published: (2016-03-01)

Novel imaging and circulating biomarkers in hepatic malignancies
by: Winter, H
Published: (2019)